<DOC>
	<DOCNO>NCT02064985</DOCNO>
	<brief_summary>open label , single centre , randomise , Phase IV , pharmacokinetic , pharmacodynamic , safety study evaluate single multiple dos 45 , 60 , 90 mg ticagrelor Chinese patient stable coronary heart disease</brief_summary>
	<brief_title>Ticagrelor China Pharmacokinetic/Pharmacodynamic Study</brief_title>
	<detailed_description>Up 36 patient randomized order ensure 10 patient per treatment evaluable.Ticagrelor supply 45 mg , 60mg , 90mg tablet . Following 8 hour fast single dose Day 1 Day 7 ; multiple dos Day 3 Day 6 . Prior first dose study drug screen period maximum 19 day . Patients report clinical pharmacology unit ( CPU ) Day -2 remain confined completion study procedure Day 7 , patient discharge Day 8 . In addition , patient return CPU follow visit 2 5 day last dose . Each patient participation , include screen period , take approximately 33 day .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision sign date write informed consent prior study specific procedure . 2 . Female male Chinese ( define Chinese Regulatory ) patient age 18 year older suitable vein cannulation repeat venipuncture . 3 . Documented stable coronary heart disease ( CHD ) fulfil follow , take 75100 mg ASA daily treatment : Diagnosed stable angina pectoris per guidance Chinese Society Cardiology publish 2007 , patient angina severity classify I II Canadian Cardiovascular Society grade angina pectoris . 4 . Female patient without pregnant potential 1 . Any indication oral anticoagulant dual antiplatelet treatment chronic ASA dose great 100 mg/day . 2 . Concomitant therapy strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer within 14 day precede first dose study medication study treatment . 3 . Increased bleeding risk . 4 . Contraindication reason ASA ticagrelor administer 5 . Patients schedule revascularization ( eg , PCI , CABG ) study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>